These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27147713)

  • 1. Cefepime-Induced Neurotoxicity Despite Dose Adjustment for Renal Disease: A Brief Report and Review of the Literature.
    Lindsay H; Gruner S; Brackett J
    J Pediatric Infect Dis Soc; 2017 Jun; 6(2):199-201. PubMed ID: 27147713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime neurotoxicity despite renal adjusted dosing.
    Gangireddy VG; Mitchell LC; Coleman T
    Scand J Infect Dis; 2011 Oct; 43(10):827-9. PubMed ID: 21604923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible coma secondary to cefepime neurotoxicity.
    Abanades S; Nolla J; Rodríguez-Campello A; Pedro C; Valls A; Farré M
    Ann Pharmacother; 2004 Apr; 38(4):606-8. PubMed ID: 14982986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients.
    Muldoon EG; Epstein L; Logvinenko T; Murray S; Doron SI; Snydman DR
    Anaerobe; 2013 Dec; 24():79-81. PubMed ID: 24140078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review.
    Lam S; Gomolin IH
    Pharmacotherapy; 2006 Aug; 26(8):1169-74. PubMed ID: 16863493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime: a rare cause of encephalopathy.
    McNally A; Pithie A; Jardine D
    Intern Med J; 2012 Jun; 42(6):732-3. PubMed ID: 22697161
    [No Abstract]   [Full Text] [Related]  

  • 7. Cefepime-induced encephalopathy in end-stage renal disease patients.
    Nakagawa R; Sato K; Uesaka Y; Mitsuki T; Kondo K; Wake A; Ubara Y; Kanzaki M
    J Neurol Sci; 2017 May; 376():123-128. PubMed ID: 28431597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal failure is a risk factor for cefepime-induced encephalopathy.
    Garces EO; Andrade de Anzambuja MF; da Silva D; Bragatti JA; Jacoby T; Saldanha Thomé F
    J Nephrol; 2008; 21(4):526-34. PubMed ID: 18651542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric cefepime neurotoxicity.
    Landgrave LC; Lock JL; Whitmore JM; Belcher CE
    Pediatr Neurol; 2012 Dec; 47(6):458-60. PubMed ID: 23127270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime-related encephalopathy in peritoneal dialysis patients.
    Lin CJ; Chen SP; Wang SJ; Fuh JL
    J Chin Med Assoc; 2011 Feb; 74(2):87-90. PubMed ID: 21354086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: case report, pharmacokinetic modeling, and review of the literature.
    Mani LY; Kissling S; Viceic D; Vogt B; Burnier M; Buclin T; Renard D
    Hemodial Int; 2015 Apr; 19(2):333-43. PubMed ID: 25052578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neurotoxicity and safety of treatment with cefepime in patients with renal failure.
    Sonck J; Laureys G; Verbeelen D
    Nephrol Dial Transplant; 2008 Mar; 23(3):966-70. PubMed ID: 18175786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonconvulsive status epilepticus during cephalosporin therapy.
    Primavera A; Cocito L; Audenino D
    Neuropsychobiology; 2004; 49(4):218-22. PubMed ID: 15118360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is cefepime safe for clinical use? A Bayesian viewpoint.
    Kalil AC
    J Antimicrob Chemother; 2011 Jun; 66(6):1207-9. PubMed ID: 21471137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.
    Rhodes NJ; Kuti JL; Nicolau DP; Neely MN; Nicasio AM; Scheetz MH
    J Infect Chemother; 2016 Feb; 22(2):78-83. PubMed ID: 26712584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime-induced neurotoxicity: a systematic review.
    Payne LE; Gagnon DJ; Riker RR; Seder DB; Glisic EK; Morris JG; Fraser GL
    Crit Care; 2017 Nov; 21(1):276. PubMed ID: 29137682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefepime-induced neurotoxicity in a patient with coronary artery bypass.
    Shah M; Shah H; Maslekar A
    Indian J Pharmacol; 2016; 48(5):599-600. PubMed ID: 27721551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem.
    Tanaka A; Takechi K; Watanabe S; Tanaka M; Suemaru K; Araki H
    Int J Clin Pharm; 2013 Oct; 35(5):683-7. PubMed ID: 23733559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study.
    Huwyler T; Lenggenhager L; Abbas M; Ing Lorenzini K; Hughes S; Huttner B; Karmime A; Uçkay I; von Dach E; Lescuyer P; Harbarth S; Huttner A
    Clin Microbiol Infect; 2017 Jul; 23(7):454-459. PubMed ID: 28111294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.